Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Key Points

This correction addresses errors in the reporting of NfL data and neurodegeneration outcomes in SMA.
Phase 3 randomized trial evaluating high-dose nusinersen in spinal muscular atrophy.
Comparison includes data from the ENDEAR matched sham group.
Corrected the reduction in neurodegeneration from 30% to 32% compared to the sham group; p=0.0075.
Adjusted nominally significant p-value for later-onset SMA neurodegeneration from 0.0495 to 0.0047.

Randomized trial corrects neurodegeneration outcomes in spinal muscular atrophy, highlighting data accuracy issues.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Finkel et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share